scPharmaceuticals (SCPH)

• Market cap: $164M
• 1 day: -0.61%
• 5 days: -0.30%
• 1 month: -4.39%
• 3 months: -25.17%
• 6 months: -34.21%
• Year to date: -8.40%
• 1 year: -39.33%
• 5 years: -40.55%
• 10 years: -76.81%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.

Employees: 96

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

368% more call options, than puts

Call options by funds: $721K | Put options by funds: $154K

317% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 6

100% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]

50% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 22

39% more capital invested

Capital invested by funds: $122M [Q2] → $170M (+$47.8M) [Q3]

23% more funds holding

Funds holding: 77 [Q2] → 95 (+18) [Q3]

3.32% less ownership

Funds ownership: 77.81% [Q2] → 74.49% (-3.32%) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 267% upside
• Avg. target: $15 359% upside
• High target: $18 450% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Douglas Tsao 36% 1-year accuracy 63 / 175 met price target	450% upside $18	Buy Reiterated	14 Nov 2024
Craig-Hallum Chase Knickerbocker 54% 1-year accuracy 14 / 26 met price target	267% upside $12	Buy Maintained	14 Nov 2024